Chelsea Counsel Co. Sells 20,000 Shares of GSK PLC Sponsored ADR $GSK

Key Points

• Chelsea Counsel Co. significantly reduced its holdings in GSK PLC by selling 20,000 shares, resulting in a 68.1% decrease in its position.
• GSK reported earnings per share of $1.23 for the last quarter, surpassing analysts' expectations of $1.12, while also achieving revenues of $10.64 billion.
• The company announced a quarterly dividend of $0.4206 per share, which equates to an annualized dividend of $1.68 and a yield of 4.1%.

Chelsea Counsel Co. cut its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 68.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,360 shares of the pharmaceutical company's stock after selling 20,000 shares during the quarter. Chelsea Counsel Co.'s holdings in GSK were worth $366,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. HHM Wealth Advisors LLC lifted its holdings in shares of GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of GSK in the 1st quarter valued at $31,000. Richardson Financial Services Inc. raised its stake in GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC acquired a new stake in GSK during the 1st quarter worth $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its position in GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Down 1.6%

Shares of NYSE GSK traded down $0.67 during mid-day trading on Friday, hitting $40.81. The company's stock had a trading volume of 4,741,956 shares, compared to its average volume of 3,553,270. The company's fifty day simple moving average is $38.74 and its 200-day simple moving average is $38.46. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $43.62. The stock has a market cap of $83.12 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 2.07 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's revenue was up 1.3% on a year-over-year basis. During the same period last year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analyst Ratings Changes

A number of research firms recently commented on GSK. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.